AUCTORES
Globalize your Research
Review | DOI: https://doi.org/10.31579/2578-8949/075
Department of dermatology, Saudi German hospitals and clinics, Hessa Street 331 West, Al Barsha 3, Exit 36 Sheikh Zayed Road, Opposite of American School, Dubai, United Arab Emirates.
*Corresponding Author: Piyu Parth Naik, Department of dermatology, Saudi German hospitals and clinics, Hessa Street 331 West, Al Barsha 3, Exit 36 Sheikh Zayed Road, Opposite of American School, Dubai, United Arab Emirates.
Citation: Piyu P Naik. (2021) Tyrosine kinase inhibitors in dermatology: A systemic review. Dermatology and Dermatitis. 6(1); Doi:10.31579/2578-8949/075
Copyright: © Piyu Parth Naik, This is an open-access article distributed under the terms of The Creative Commons. Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 05 May 2021 | Accepted: 21 May 2021 | Published: 24 May 2021
Keywords: tyrosine kinase inhibitors; jak inhibitors; alopecia areata; atopic dermatitis; baricitinib; psoriasis; ruxolitinib; tofacitinib; vitiligo
The inhibition of enzyme subgroups of tyrosine kinases can block the ability of various cytokines at the same time. Tyrosine kinase inhibitors are a class of drugs that can be used either primarily as oral medicines or in dermatological definitions locally. In several skin problems, restraint of tyrosine kinases has been demonstrated to be advantageous. Aim of this article is to explore the role of tyrosine kinase inhibitors in various skin diseases. Tyrosine inhibitors have demonstrated a guaranteed response in psoriasis, alopecia areata, Vitiligo, while the variable response in other skin disorders, including atopic dermatitis, chronic actinic dermatitis, dermatomyositis, erythema multiforme, graft-versus-host disease, hypereosinophillic syndrome, STING vasculopathy, palmoplantar pustulosis and lupus. The approach of Tyrosine inhibitors in dermatology has been met with incredible interest. This class of prescriptions can generously propel the treatment of inflammatory and immune mediated dermatoses. It is still too early to make a strong inference regarding these medicines' place in dermatological treatment, even though the evidence provides promising results.
Our understanding of the pathogenesis of provocative and immunological infections has gained extraordinary advancement over recent years, thus revealing novel remedial goals. Protein tyrosine kinases (PTKs) handle cell multiplication, immune response and bolstering signaling in cells within theoretical models. Unchecked movements from tyrosine kinase receptors and intracellular tyrosine kinases can lead to fiery reactions of cytokines and lead to autoimmune diseases, dermatitis and even malignancy [1].
The Tyrosine kinase inhibitors, necessary for the downstream motioning of inflammatory cytokines, are among late perceived targets [1]. In dermatology, tyrosine kinase inhibitors have their spot in the blockage of cytoplasmic Janus kinases, which is a subclass of huge tyrosine kinase family. Various investigators have thought about aiming Janus kinases or JAKs starting late due to promising initial results. New disclosures in JAK-STAT pathway and the improvement of medications that block their related activity have made new entryways for treating issues related to this system's dysregulation [2].
After clinical fundamentals performed, with first generation of JAK inhibitors like tofacitinib, ruxolitinib, baricitinib and oclacitinib, dermatological conditions like psoriasis and atopic dermatitis, received the dermatology field's most significant advantage [2].
Another condition that has shown promising outcomes from treatment with JAK-inhibitors is Alopecia areata (AA). Other immune mediated cutaneous disorders where JAK-inhibitors are useful include Vitiligo, atopic dermatitis (AD), chronic actinic dermatitis, chronic mucocutaneous candidiasis, cutaneous T-cell lymphoma, dermatomyositis, hypereosinophillic syndrome, cutaneous Graft Versus Host Disease (GVHD), cutaneous mastocytosis, palmoplantar pustulosis, STING vasculopathy, and lupus erythematosus [2].
The current systematic review has followed Preferred Reporting Items for Systematic Reviews (PRISMA) method [3]. A systematic review comprises the structured collection of evidence-based articles followed by systematically discussing their findings based on the review's aim.
An articles search was undertaken electronically using online databases such as Google Scholar, MEDLINE, PubMed, Scopus and Cochrane databases with the appropriate key terms (MeSH). We were looking specifically for articles on Tyrosine kinase inhibitors in dermatology. The keywords were changed according to each database's searching protocol, including "Tyrosine kinase inhibitors," "JAK inhibitors," "Dermatology." Bibliographic sources were also screened.
The articles published related to Tyrosine kinase inhibitors in dermatology were included in this review. The research articles, case studies, studies related to other than dermatological disorders, review and systematic review and articles published other than the English language were excluded in this study.
The initial literature search revealed 717 articles. Relevant articles were chosen for full-text screening after the application of the eligibility criteria.
The literature search yielded 717 articles from various databases, including PubMed, Ovid, Science Direct and Google Scholar, of which 305 articles were excluded at the initial stage due to repetition and irrelevance. Out of 412, 278 articles were further excluded after analyzing the titles and abstracts at the first screening level. Finally, 134 studies meeting the current systematic review's inclusion criteria as detailed in the PRISMA flow chart were included in this review. (Figure 1)
The references to each relating articles have additionally been looked up. Furthermore, clinical trials were further used to look for clinical preliminaries.
Our hunt yielded 134 items, comprising 44 review articles, 78 unique original articles (53 clinical investigations and 25 preclinical examinations in vitro and in vivo), and 12 reports on adverse events.
Among the clinical examinations (43%) and clinical trials (38.7%), Psoriasis was the most well-known skin disease found, which responded to this group of medicines. The other common condition considered in preclinical investigations was dermatitis (Table 1).
The adequacy of Tyrosine Kinase inhibitors in the treatment of skin and hair problems was accounted for in 29 of the 46 papers recognized.
The pathway of tyrosine kinase and associated cytokines to action and dysregulation has been connected as a potential psoriasis disease component. Either oral or topically administered tyrosine kinase inhibitors have been beneficial in the treatment of Psoriasis. The most extensively read finished paperwork for Tyrosine Kinase inhibitors in dermatology have been in the subject of Psoriasis to date.
The efficacy of oral tofacitinib was studied in chronic plaque psoriasis in phase 3 randomized controlled trials by Papp et al. in 2015, which showed noteworthy effectiveness in patients with moderate-to-severe psoriasis [4]. In another assessment by Bachelet et al., the Psoriasis Area Severity Index (PASI) responded to oral tofacitinib by 39.5% in 5 mg dose group and 63.6 % in 10 mg dose group at 12 weeks [5]. Tofacitinib in 10 mg dosage was non-inferior to etanercept therapy in moderate-severe cases of plaque psoriasis [5]. For the 5 mg and 10 mg divided frameworks of tofacitinib, adversarial events were similar for tofacitinib and etanercept [5]. Similar improvement was also observed in another study done by Boy et al [6]. However, FDA has not yet approved tofacitinib for psoriasis and its role still remains investigational till date.
Vesely et al. observed substantial improvement in a refractory, severe case of chronic actinic dermatitis to tofacitinib [7]. Infect, same patient was put on multiple immunomodulatory agents prior to tofacitinib administration, which shows zenith of JAK inhibitors, especially tofacitinib [7].
Role of tofacitinib in cutaneous manifestations of polyarteritis nodosa (PAN) was highlighted by Rimar et al. in 2016 [8]. A young adult with chronic symptoms of livedo reticularis and skin nodules, previously treated with azathioprine and methotrexate in remission when showed flaring up of disease showed response to tofacitinib [8].
Seventeen examinations were assessed for the utilization of tyrosine kinase inhibitors in AA. Harel et al observed that local treatment of human and mouse skin with JAK-inhibitors culminated in swift transition of anagen phase of hair cycle and hence hair growth [9]. Core pathogenesis of alopecia areata by interferon gamma and gamma chain cytokine receptors was studied by Xing et al., which also demonstrated the positive role of JAK inhibitors in hair regrowth and turnaround of entrenched AA [10]. These outcomes can clarify the rationale and benefits of tyrosine kinase inhibitors therapy in patients with AA. Sixty-six patients with AA treated by tofacitinib were assessed by Crispin et al. in open -label study in 2016. The impact of tofacitinib was significant. In 32 percent of patients, significant improvement was illustrated in form of regrowth of scalp hair. [11].
Another investigation, including 90 AA patients treated with Tofacitinib, announced clinical response in 77% of cases. In this particular study, response in AA was more marked in comparison to alopecia totalis or alopecia universalis [12]. Additionally, Craiglow et al. displayed the encouraging role of tofacitinib in teenage group cases of AA [13].
In a pilot study, ruxolitinib was given to 12 patients of moderate-to-severe alopecia areata. Striking hair regrowth was seen in 9 patients after 3 to 6 months of treatment with ruxolitinib [14]. Additional investigation on eyebrow and scalp with ruxolitinib brought complete eyebrow hair regrowth and 10% of scalp hair regrowth [15].
Study done by Jabbari et al. illustrated that another tyrosine kinase inhibitor named Baricitinib may be fruitful treatment of AA [16]. Same Baricitinib also attained remarkable amelioration in moderate-to-severe patients of psoriasis and PASI-75 showed revamp after 12 weeks of treatment [17, 18].
JAK inhibitor, tofacitinib showed marked repigmentation in a case of vitiligo, which was attributed to modern discovery in pathogenesis of vitiligo [19]. Similar efficacy of oral ruxolitinib was visualized in a case of coexistent vitiligo and AA by Harris et al [20]. Recent clinical trial by Rosmarin et al. showed successful repigmentation of vitiligo patches with ruxolitinib cream [21].
Reduction in the overall surface area of dermatitis with associated reduction of excoriation and erythema as well as lichenification was detected after Oral tofacitinib usage in recalcitrant atopic dermatitis with 66.6% reduction in AD index [22]. Bissonnette et al. noticed pronounced effectiveness of tofacitinib ointment for atopic dermatitis in a randomized trial [23]. They even considered topical route propitious in atopic dermatitis cases [23].
Ruxolitinib was triumphant against a difficult-to-treat case of chronic mucocutaneous candidiasis as reported by Mossner et al. with IL-6 being used as feedback variable [24].
Cutaneous T cell lymphoma are a subgroup which comes under the broad heading of non-Hodgkin lymphoma which harbors mutations in T cell receptor complex and JAK-STAT signaling pathways. These collectively make tyrosine kinase inhibitors exciting novel weapon against cutaneous T cell lymphoma. However, this prospective functionality needs future trials [25].
Kurtzman et al. delineated foremost utilization of tofacitinib in treatment of refractory dermatomyositis [26]. Likewise, revocation of recalcitrant dermatomyositis was discovered by Hornung et al., when Ruxolitinib was dispensed in a case of myelofibrosis where dermatomyositis was associated finding [27].
Tofacitinib treatment in 10 mg dosage led to full recovery in a case of idiopathic recurrent erythema multiforme as stated by Damsky et al [28]. A multicenter survey exhibited the positive role of ruxolitinib in steroid resistant cutaneous findings of graft-versus-host disease after stem cell transplantation [29]. Reduction in blood eosinophilic count as well as improvement in dermatitis and itching was depicted after treatment with JAK inhibitors in hypereosinophillic syndrome with dermatological manifestations [30].
Chilblain lupus erythematosus, which is a rare autoimmune disorder, was also controlled by ruxolitinib treatment as stated by Wenzel et al [31]. Ruxolitinib also improves quality of life and symptoms in systemic mastocytosis [32]. Even rarer STING vasculopathy which is linked with TMEM1J3 mutation, improved with ruxolitinib in three children [33]. Koga et al. reported therapeutic favorable outcome in patients of palmoplantar pustulosis treated by JAK inhibitors [34].
Thus, Tyrosine kinase inhibitors are now a major class of drugs in dermatology treating a plethora of cutaneous conditions. (Table 2)
Though tyrosine kinase inhibitors have many applications in the vast field of dermatology, this group is not free of side effects. Though tyrosine kinase inhibitors used in clinical oncology have predominant skin and cardiovascular toxicities, TKI which are having skin applications do not demonstrate them [35-38].
Ruxolitinib was most commonly associated with urinary tract infection when it was used in treating myelofibrosis [39]. On the other hand, tofacitinib increased the risk of reactivation stage of varicella zoster virus [40]. Response to vaccination could be impeded with tofacitinib and ruxolitinib, which requires healthcare strategist to plan vaccinations before starting treatment with these tyrosine kinase inhibitors [41].
As JAK2 inhibition is more profound with ruxolitinib as compared with tofacitinib, cytopenia, which is primarily mediated by JAK2, is more common with ruxolitinib [42]. However, in a study carried out by Mackay-Wiggan et al. AA dealt with ruxolitinib in therapeutic doses did not demonstrate cytopenia [14].
Neoplasia risk is definitely a reason of apprehension among scientists with the use of Tyrosine kinase inhibitors, albeit theoretically. 1% of renal transplant patients treated with tofacitinib developed post-transplant lympho-proliferative disorder [43]. Nevertheless, no obvious malignancy risk was perceptible when tofacitinib or ruxolitinib were used to treat inflammatory diseases till date [44-47].
Conclusions:
Tyrosine inhibitors have demonstrated response in multiple skin disorders, including Psoriasis, alopecia areata and Vitiligo. Clinical information indicates that the treatment of numerous other dermatological conditions can be achieved through tyrosine hindrance. The approach of Tyrosine inhibitors in dermatology has been met with incredible interest. This class of prescriptions can generously propel the treatment of inflammatory and immune mediated dermatoses. Another exhilarating age of JAK inhibitors/ tyrosine kinase inhibitors is in progress.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
